Ryan Tulowitzki, DO
Nephrology · Mobile, ALNPI 1134488521
Payments from drug & device makers
Across 122 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$831
- AstraZeneca$263
- Otsuka America Pharmaceutical, Inc.$258
- Daiichi Sankyo Inc.$181
- Bard Peripheral Vascular, Inc.$137
- Akebia Therapeutics Inc$123
- plus $603 from 15 others
What the payments were for
- Food & beverage$2,30496%
- Education$944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 48 | $831 |
| AstraZeneca(2 entities) | 15 | $263 |
| Otsuka America Pharmaceutical, Inc. | 13 | $258 |
| Daiichi Sankyo Inc. | 9 | $181 |
| Bard Peripheral Vascular, Inc. | 1 | $137 |
| Akebia Therapeutics Inc | 7 | $123 |
| Fresenius USA Marketing, Inc. | 6 | $89 |
| Nxstage Medical, Inc. | 1 | $85 |
| Bayer | 3 | $72 |
| Novartis | 3 | $71 |
| Vifor Pharma, Inc. | 4 | $56 |
| OPKO Pharmaceuticals, LLC | 3 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $30 |
| Mozarc Medical US LLC | 1 | $23 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| Sanofi | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Aurinia Pharma U.S., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$105
How this compares
$2,397 in reported general payments places this provider in the 45th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 141 | $135,466 |
| AuryxiaFerric Citrate | 52 | $125,906 |
| VelphoroSucroferric Oxyhydroxide | 19 | $62,769 |
| JardianceEmpagliflozin | 59 | $54,793 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $23,565 |
| Sevelamer Carbonate | 56 | $10,867 |
| Calcium Acetate | 21 | $2,734 |
| Hydralazine Hcl | 113 | $1,935 |
| Midodrine Hcl | 31 | $1,585 |
| Calcitriol | 65 | $1,310 |
| Carvedilol | 145 | $1,303 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,203 |
| Losartan Potassium | 121 | $1,198 |
| Cyproheptadine Hcl | 42 | $1,185 |
| Nifedipine ErNifedipine | 26 | $1,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $263 | $159,032174 claims |
| Akebia Therapeutics IncAuryxia | $123 | $125,90652 claims |
| Fresenius USA Marketing, Inc.Velphoro | $89 | $62,76919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 164 nephrology providers in Alabama.
Other nephrology in Mobile
- Michael KleinmannMobile$50K
- Andrew FelisMobile$35K
- Roy CulpepperMobile$21K
- Douglas AmareMobile$10K
- Purnima TripathyMobile$5K
- Christopher MireMobile$5K
- Richard MeadorMobile$4K
- David TietjenHuntsville$2.6M
- Dana RizkBirmingham$2.6M
- Michael QuadriniHuntsville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.